SI3029154T1 - Method for identifying patient sensitivity to telomerase inhibition therapy - Google Patents
Method for identifying patient sensitivity to telomerase inhibition therapy Download PDFInfo
- Publication number
- SI3029154T1 SI3029154T1 SI200931745T SI200931745T SI3029154T1 SI 3029154 T1 SI3029154 T1 SI 3029154T1 SI 200931745 T SI200931745 T SI 200931745T SI 200931745 T SI200931745 T SI 200931745T SI 3029154 T1 SI3029154 T1 SI 3029154T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cancer
- component
- telomer
- adverse reaction
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 22
- 230000005764 inhibitory process Effects 0.000 title claims 9
- 238000002560 therapeutic procedure Methods 0.000 title claims 9
- 108010017842 Telomerase Proteins 0.000 title claims 8
- 230000035945 sensitivity Effects 0.000 title claims 2
- 206010067484 Adverse reaction Diseases 0.000 claims abstract 11
- 230000006838 adverse reaction Effects 0.000 claims abstract 11
- 229940123582 Telomerase inhibitor Drugs 0.000 claims abstract 7
- 239000003277 telomerase inhibitor Substances 0.000 claims abstract 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 241000124008 Mammalia Species 0.000 claims 5
- 206010043554 thrombocytopenia Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical group N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 229950004291 imetelstat Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 210000003411 telomere Anatomy 0.000 abstract 1
- 102000055501 telomere Human genes 0.000 abstract 1
- 108091035539 telomere Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Epidemiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Hematology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10649108P | 2008-10-17 | 2008-10-17 | |
| EP15202042.6A EP3029154B1 (en) | 2008-10-17 | 2009-10-13 | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3029154T1 true SI3029154T1 (en) | 2018-02-28 |
Family
ID=42106854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931745T SI3029154T1 (en) | 2008-10-17 | 2009-10-13 | Method for identifying patient sensitivity to telomerase inhibition therapy |
| SI200931386T SI2342360T1 (sl) | 2008-10-17 | 2009-10-13 | Metoda za identifikacijo občutljivosti bolnika na terapijo inhibicije telomeraze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931386T SI2342360T1 (sl) | 2008-10-17 | 2009-10-13 | Metoda za identifikacijo občutljivosti bolnika na terapijo inhibicije telomeraze |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US8877723B2 (enExample) |
| EP (4) | EP2342360B1 (enExample) |
| CY (2) | CY1117234T1 (enExample) |
| DK (2) | DK3029154T3 (enExample) |
| ES (4) | ES2566338T3 (enExample) |
| HR (2) | HRP20160067T1 (enExample) |
| HU (2) | HUE027213T2 (enExample) |
| LT (1) | LT3029154T (enExample) |
| NO (1) | NO3029154T3 (enExample) |
| PL (2) | PL2342360T3 (enExample) |
| PT (3) | PT3719139T (enExample) |
| SI (2) | SI3029154T1 (enExample) |
| SM (2) | SMT201700535T1 (enExample) |
| WO (1) | WO2010045245A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014085632A1 (en) * | 2012-11-30 | 2014-06-05 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| KR20250151565A (ko) | 2017-07-28 | 2025-10-21 | 제론 코포레이션 | 골수형성이상 증후군의 치료 방법 |
| CN109662968B (zh) * | 2017-10-13 | 2021-05-18 | 上海奥奇医药科技有限公司 | 含A-失碳-5α雄甾烷化合物的升白制剂及其应用 |
| AU2019389005B2 (en) | 2018-11-29 | 2024-06-20 | Geron Corporation | Methods of treating myelodysplastic syndrome |
| KR20230041707A (ko) * | 2020-07-17 | 2023-03-24 | 제론 코포레이션 | 피하 텔로머라제 억제제 조성물 및 이의 사용 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5776679A (en) | 1994-07-07 | 1998-07-07 | Geron Corporation | Assays for the DNA component of human telomerase |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| ATE362546T1 (de) | 1995-10-12 | 2007-06-15 | Lansdorp Peter M | Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| JP2001507229A (ja) | 1996-12-20 | 2001-06-05 | ジェロン コーポレイション | テロメラーゼのｒｎａ成分を検出および阻害するための方法 |
| US6156763A (en) * | 1998-02-04 | 2000-12-05 | Board Of Regents, The University Of Texas System | Inhibition of human telomerase by a g-quadruplex-interaction compound |
| US6995145B1 (en) | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
| DK1210357T3 (da) | 1999-09-10 | 2008-07-21 | Geron Corp | Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| PT1282443E (pt) | 2000-05-19 | 2009-12-04 | Genentech Inc | Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| US9777312B2 (en) * | 2001-06-30 | 2017-10-03 | Enzo Life Sciences, Inc. | Dual polarity analysis of nucleic acids |
| CA2474468C (en) | 2002-01-31 | 2014-03-25 | University Of Utah | Amplifying repetitive nucleic acid sequences |
| US20040234961A1 (en) | 2002-04-22 | 2004-11-25 | Fordyce Colleen A. | Telomere length determination and applications |
| US9169516B2 (en) | 2003-01-24 | 2015-10-27 | University Of Utah Research Foundation | Methods of predicting mortality risk by determining telomere length |
| KR101298493B1 (ko) | 2003-09-09 | 2013-08-21 | 제론 코포레이션 | 텔로머라제 억제를 위한 변형 올리고뉴클레오티드 |
| ME02933B (me) | 2004-07-02 | 2018-04-20 | Geron Corp | Sinteza zaštićenih 3'-amino nukleozionih monomera |
| DE102005024834B3 (de) | 2005-05-31 | 2007-01-04 | Lucas Automotive Gmbh | Verfahren und System zur Steuerung einer Kraftfahrzeug-Feststellbremse während eines Halts |
| NZ565654A (en) * | 2005-07-18 | 2010-10-29 | Bipar Sciences Inc | Use of iodonitrobenzamide compounds for the treatment of ovarian cancer |
| BRPI0619476A2 (pt) | 2005-12-05 | 2011-10-04 | Wyeth Corp | composições de interleucina-11 e métodos de uso |
| ES2407957T3 (es) * | 2007-03-09 | 2013-06-17 | Geron Corporation | Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa |
| US20100291560A1 (en) | 2007-03-27 | 2010-11-18 | The Johns Hopkins University | Methods and compositions for diagnosis and treatment of dyskeratosis congenita and related disorders |
| WO2009073751A2 (en) | 2007-12-04 | 2009-06-11 | Geron Corporation | Hair follicle pharmacodynamic assay for telomerase activity |
| US20090298709A1 (en) | 2008-05-28 | 2009-12-03 | Affymetrix, Inc. | Assays for determining telomere length and repeated sequence copy number |
| US20110207128A1 (en) | 2010-02-16 | 2011-08-25 | Cawthon Richard M | Methods and kits for determining biological age and longevity based on gene expression profiles |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| WO2014085632A1 (en) | 2012-11-30 | 2014-06-05 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
-
2009
- 2009-10-13 NO NO15202042A patent/NO3029154T3/no unknown
- 2009-10-13 ES ES09821131.1T patent/ES2566338T3/es active Active
- 2009-10-13 EP EP09821131.1A patent/EP2342360B1/en active Active
- 2009-10-13 PT PT201564945T patent/PT3719139T/pt unknown
- 2009-10-13 PL PL09821131T patent/PL2342360T3/pl unknown
- 2009-10-13 SI SI200931745T patent/SI3029154T1/en unknown
- 2009-10-13 PT PT171945876T patent/PT3330383T/pt unknown
- 2009-10-13 ES ES15202042.6T patent/ES2645872T3/es active Active
- 2009-10-13 HU HUE09821131A patent/HUE027213T2/en unknown
- 2009-10-13 DK DK15202042.6T patent/DK3029154T3/en active
- 2009-10-13 SI SI200931386T patent/SI2342360T1/sl unknown
- 2009-10-13 WO PCT/US2009/060526 patent/WO2010045245A1/en not_active Ceased
- 2009-10-13 LT LTEP15202042.6T patent/LT3029154T/lt unknown
- 2009-10-13 ES ES20156494T patent/ES2939509T3/es active Active
- 2009-10-13 EP EP20156494.5A patent/EP3719139B1/en active Active
- 2009-10-13 EP EP15202042.6A patent/EP3029154B1/en active Active
- 2009-10-13 EP EP17194587.6A patent/EP3330383B1/en active Active
- 2009-10-13 DK DK09821131.1T patent/DK2342360T3/en active
- 2009-10-13 SM SM20170535T patent/SMT201700535T1/it unknown
- 2009-10-13 PT PT152020426T patent/PT3029154T/pt unknown
- 2009-10-13 ES ES17194587T patent/ES2789580T3/es active Active
- 2009-10-13 US US13/124,376 patent/US8877723B2/en active Active
- 2009-10-13 HR HRP20160067T patent/HRP20160067T1/hr unknown
- 2009-10-13 PL PL15202042T patent/PL3029154T3/pl unknown
- 2009-10-13 HU HUE15202042A patent/HUE037447T2/hu unknown
-
2014
- 2014-10-02 US US14/505,366 patent/US9617583B2/en active Active
-
2016
- 2016-03-01 CY CY20161100171T patent/CY1117234T1/el unknown
- 2016-03-24 SM SM201600087T patent/SMT201600087B/it unknown
-
2017
- 2017-02-28 US US15/445,428 patent/US10196677B2/en active Active
- 2017-10-11 HR HRP20171536TT patent/HRP20171536T1/hr unknown
- 2017-11-07 CY CY20171101163T patent/CY1119653T1/el unknown
-
2018
- 2018-12-20 US US16/227,778 patent/US20190382829A1/en not_active Abandoned
-
2020
- 2020-09-23 US US17/029,815 patent/US20210269861A1/en not_active Abandoned
-
2021
- 2021-11-23 US US17/533,825 patent/US20220325327A1/en not_active Abandoned
-
2022
- 2022-05-24 US US17/752,106 patent/US20230114322A1/en not_active Abandoned
-
2023
- 2023-10-20 US US18/491,658 patent/US20240318232A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3029154T1 (en) | Method for identifying patient sensitivity to telomerase inhibition therapy | |
| Cui et al. | Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor | |
| Eyles et al. | Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma | |
| e Silva et al. | Assessment of kidney function in patients with cancer | |
| Mesti et al. | Metabolic impact of anti-angiogenic agents on U87 glioma cells | |
| Sedrak et al. | Measuring biologic resilience in older cancer survivors | |
| Baumgartner et al. | Novel insights into diagnosis, biology, and treatment of primary diffuse leptomeningeal melanomatosis | |
| Ahnach et al. | Extramedullary plasmocytoma relapsing at differents sites: an unusual presentation | |
| Joo et al. | Relationships between tumor volume and lymphatic metastasis and prognosis in early oral tongue cancer | |
| Lai et al. | IFIT2‐depleted metastatic oral squamous cell carcinoma cells induce muscle atrophy and cancer cachexia in mice | |
| MacFie et al. | Body composition in malignant disease | |
| Chandrasekaran et al. | 18F‐Fluorothymidine‐Pet Imaging of Glioblastoma Multiforme: Effects of Radiation Therapy on Radiotracer Uptake and Molecular Biomarker Patterns | |
| Petronek et al. | Assessment of gadobutrol safety in combination with ionizing radiation using a preclinical MRI-guided radiotherapy model | |
| Peet et al. | Measuring foetal dose from tomotherapy treatments | |
| Ida et al. | Abdomen specific bioelectrical impedance analysis (BIA) methods for evaluation of abdominal fat distribution | |
| Miura et al. | Performance evaluation of MVision AI Contour+ in gastric MALT lymphoma segmentation | |
| Khurana et al. | Cisplatin induced renal insufficiency measured by glomerular filtration rate with 99mTc-DTPA and by using serum creatinine based formulae: a prospective study | |
| Ward et al. | Serum AFP and apparent half life estimates in the management of endodermal sinus tumours | |
| Yun et al. | Spontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma | |
| Shcherbakov et al. | Some Physical Factors in the Development of Secondary Cancers in Patients Who Have Undergone Radiation Therapy | |
| Agarwal et al. | Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex | |
| YU et al. | Study on Lugol's Iodine Enhanced Micro-CT Imaging for Evaluating Margin Status of Oral Squamous Cell Carcinoma | |
| RU2297001C1 (ru) | Способ определения динамики изменений интенсивности транспорта веществ в превалирующих направлениях между кровью и неминерализованными органами | |
| Rich et al. | Reply: Wang et al,“Should growth pattern of hepatocellular carcinoma be constant and homogenous?” | |
| Lee et al. | Real Time Two-Dimensional Shear Wave Elastography in Patients with Acute Hepatitis. |